Wall Street analysts expect that China Biologic Products Holdings Inc (NASDAQ:CBPO) will post earnings of $0.88 per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for China Biologic Products’ earnings. China Biologic Products reported earnings per share of $0.96 during the same quarter last year, which suggests a negative year over year growth rate of 8.3%. The firm is expected to report its next quarterly earnings results on Thursday, November 7th.

According to Zacks, analysts expect that China Biologic Products will report full-year earnings of $4.17 per share for the current year, with EPS estimates ranging from $3.94 to $4.40. For the next financial year, analysts forecast that the firm will post earnings of $4.38 per share, with EPS estimates ranging from $4.30 to $4.45. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow China Biologic Products.

China Biologic Products (NASDAQ:CBPO) last announced its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported $1.24 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.21. The business had revenue of $135.70 million during the quarter. China Biologic Products had a return on equity of 8.56% and a net margin of 29.46%. The firm’s quarterly revenue was up 12.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.17 earnings per share.

CBPO has been the topic of a number of recent research reports. BidaskClub downgraded shares of China Biologic Products from a “buy” rating to a “hold” rating in a report on Tuesday. Zacks Investment Research cut shares of China Biologic Products from a “hold” rating to a “sell” rating in a report on Thursday, August 15th. Finally, ValuEngine downgraded shares of China Biologic Products from a “buy” rating to a “hold” rating in a research report on Wednesday, September 4th. Two equities research analysts have rated the stock with a sell rating and four have issued a hold rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $78.00.

A number of institutional investors have recently made changes to their positions in CBPO. Bank of New York Mellon Corp lifted its stake in shares of China Biologic Products by 2.1% in the second quarter. Bank of New York Mellon Corp now owns 17,276 shares of the biopharmaceutical company’s stock worth $1,647,000 after buying an additional 357 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in China Biologic Products by 446.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,761 shares of the biopharmaceutical company’s stock worth $168,000 after acquiring an additional 1,439 shares during the period. SG Americas Securities LLC bought a new position in China Biologic Products in the 2nd quarter worth $187,000. Laurion Capital Management LP acquired a new position in China Biologic Products during the 1st quarter worth $317,000. Finally, Parametrica Management Ltd acquired a new position in China Biologic Products during the 1st quarter worth $334,000. 36.90% of the stock is owned by hedge funds and other institutional investors.

CBPO stock traded down $1.06 during trading hours on Thursday, hitting $100.00. The company’s stock had a trading volume of 156,639 shares, compared to its average volume of 183,300. The stock has a 50 day moving average price of $98.07 and a two-hundred day moving average price of $93.42. China Biologic Products has a 12 month low of $60.08 and a 12 month high of $103.50. The company has a market capitalization of $4.03 billion, a PE ratio of 24.88, a price-to-earnings-growth ratio of 6.22 and a beta of 1.18.

China Biologic Products Company Profile

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Further Reading: Percentage Gainers

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.